Literature DB >> 11996787

Analysis of the NF2 gene in oligodendrogliomas and ependymomas.

M Eva Alonso1, M Josefa Bello, Dolores Arjona, Pilar Gonzalez-Gomez, Jesus Lomas, Jose M de Campos, M Elena Kusak, Alberto Isla, Juan A Rey.   

Abstract

Allelic losses of chromosome 22 are commonly found in ependymomas and oligodendrogliomas, suggesting that at least one tumor suppressor gene on chromosome 22 must be inactivated during the multistep process of tumorigenesis in these glial tumors. The neurofibromatosis 2 gene (NF2) located at 22q12, is a candidate tumor suppressor gene potentially involved in the pathogenesis of gliomas. Because there have been only a few studies of the NF2 gene in glial tumors other than astrocytoma, we screened the entire 17 NF2 exons for mutations in a series of 47 nonastrocytic tumors, including 40 oligodendrogliomas and 7 ependymomas. Only one mutation was detected, a 59-base pair insertion in exon 3 from a spinal anaplastic ependymoma. These results concur with previous findings proposing preferential inactivation of the NF2 gene in a subgroup of ependymomas, and suggest that the NF2 gene is not the target of chromosome 22 aberrations in oligodendrogliomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996787     DOI: 10.1016/s0165-4608(01)00591-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 2.  Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects.

Authors:  Yong-Chang Liu; Yan-zhou Wang
Journal:  Tumour Biol       Date:  2015-03-07

3.  A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma.

Authors:  Ilyess Zemmoura; Patrick Vourc'h; Agathe Paubel; Béatrice Parfait; Joëlle Cohen; Frédéric Bilan; Alain Kitzis; Cécilia Rousselot; Fabrice Parker; Patrick François; Christian R Andres
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 12.300

4.  Loss of 22q chromosome is related to glioma progression and loss of 10q.

Authors:  Florence Laigle-Donadey; Emmanuelle Crinière; Alexandra Benouaich; Emmanuelle Lesueur; Karima Mokhtari; Khe Hoang-Xuan; Marc Sanson
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

5.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.

Authors:  Blanca Suarez-Merino; Mike Hubank; Tamas Revesz; William Harkness; Richard Hayward; Dominic Thompson; John L Darling; David G T Thomas; Tracy J Warr
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

Review 6.  Intraventricular tanycytic ependymoma: case report and review of the literature.

Authors:  Brian T Ragel; Jeannette J Townsend; Adam S Arthur; William T Couldwell
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

8.  Aberrant CpG island methylation of multiple genes in ependymal tumors.

Authors:  M Eva Alonso; M Josefa Bello; Pilar Gonzalez-Gomez; Dolores Arjona; Jose M de Campos; Manuel Gutierrez; Juan A Rey
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Authors:  Matthieu Peyre; Frédéric Commo; Carmela Dantas-Barbosa; Felipe Andreiuolo; Stéphanie Puget; Ludovic Lacroix; Françoise Drusch; Véronique Scott; Pascale Varlet; Audrey Mauguen; Philippe Dessen; Vladimir Lazar; Gilles Vassal; Jacques Grill
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

10.  Merlin is a potent inhibitor of glioma growth.

Authors:  Ying-Ka Ingar Lau; Lucas B Murray; Sean S Houshmandi; Yin Xu; David H Gutmann; Qin Yu
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.